

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : 4,997,841
ISSUED : March 5, 1991
INVENTORS : Alexander W. Oxford, et al.
PATENT OWNER : Glaxo Wellcome Inc.
PRODUCT : AMERGE® (natriptan hydrochloride)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,997,841 based upon the regulatory review of the product AMERGE® (natriptan hydrochloride) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

694 days

from August 12, 2008, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 19th day of January 2001.

A handwritten signature in black ink, appearing to read "Q. Todd Dickinson", is written over the printed name.

Q. Todd Dickinson

Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office